Kallikrein 4 anticorps (AA 242-254)

N° du produit ABIN636259

Détail du produit anti-Kallikrein 4 anticorps

Antigène: Kallikrein 4 (KLK4) (Kallikrein-Related Peptidase 4 (KLK4))

Épitope: AA 242-254

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Kallikrein 4 est non-conjugé

Application: Western Blotting (WB)

Purification: Affinity chromatography purified

Immunogène: KLK-L1 antibody was raised in rabbit using AA 242-254 [KFTEWIEKTVQAS] of the human 39 kDa KLK-L1 (KLK4) protein as the immunogen.

Isotype: IgG

Information d'application

Indications d'application: WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: Lot specific

Buffer: Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Détails sur Kallikrein 4

Antigène: Kallikrein 4 (KLK4) (Kallikrein-Related Peptidase 4 (KLK4))

Autre désignation: KLK-L1 (KLK4 Produits)

Synonymes: anticorps ESMP1, anticorps KLK-L1, anticorps PSTS, anticorps Prss17, anticorps AI2A1, anticorps ARM1, anticorps EMSP, anticorps EMSP1, anticorps PRSS17, anticorps kallikrein, anticorps Emsp1, anticorps kallikrein related-peptidase 4 (prostase, enamel matrix, prostate), anticorps kallikrein related peptidase 4, anticorps kallikrein-related peptidase 4, anticorps Klk4, anticorps KLK4

Sujet: Kallikreins are a subgroup of serine proteases and are implicated in carcinogenesis. A novel Kallikrein gene Prostase/KLK-L1 (also known as KLK4) is expressed and is up-regulated by androgens and progestins. KLK-L1 may be involved in the pathogenesis and/or progression of prostate, breast, and possibly other malignancies.

Pathways: Système du Complément